|
Jun 01, 2023
|
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
|
May 15, 2023
|
Cyclerion Announces Reverse Stock Split
|
|
|
May 11, 2023
|
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
|
|
|
May 11, 2023
|
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
|
|
|
Apr 03, 2023
|
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
|
|
|
Mar 27, 2023
|
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
|
|
|
Mar 22, 2023
|
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
|
|
